Akebia Therapeutics Inc — Cash Flow (NASDAQ:AKBA) | MetaTrader

Open full chart Full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -110.39 M-252.97 M-73.15 M-23.38 M-40.66 M67.99 M 60.37 M Cash from investing activities -40 M39.94 M-114 K0-33 K-7.93 M -8.14 M Cash from financing activities 231.72 M133.73 M14.6 M-25.21 M49.66 M72.93 M -2.94 M Free cash flow -110.39 M-252.97 M-73.15 M-23.38 M-40.66 M67.7 M 60.04 M

News

Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates

United Therapeutics (UTHR) Misses Q1 Earnings and Revenue Estimates

Q32 Bio Gears Up to Report Q1 Earnings: What's in the Cards?

Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates

Are Options Traders Betting on a Big Move in Akebia Therapeutics Stock?

New Strong Sell Stocks for April 28th

Akebia Therapeutics, Inc. (AKBA) Discusses Pipeline Progress and Strategic Focus on Kidney Disease Treatments at R&D Day - Slideshow (NASDAQ:AKBA) 2026-04-04

Akebia Therapeutics, Inc. (AKBA) Discusses Pipeline Progress and Strategic Focus on Kidney Disease Treatments at R&D Day Transcript

Akebia Therapeutics, Inc. (AKBA) Presents at Leerink Global Healthcare Conference 2026 Transcript

Akebia at Leerink Conference: Strategic Focus on Vafseo and Pipeline

3 Best Stocks to Buy Today with 125%+ Upside, 2/27/2026, According to Top Analysts - TipRanks.com

Ardelyx (ARDX) Reports Break-Even Earnings for Q4